An interventional study of Meleis' Transition Theory-Based Education and Counseling Program and Standard Information in Menopause, Menopausal Symptoms and Perimenopausal Depression, sponsored by Ankara Medipol University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 45 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Ankara Medipol University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 343 studies in Depression with a site in Turkey — 59 open to participants now, 71 under way, none of them phase 3. Depression · Turkey.
Among the 343 studies in Depression with a site in Turkey, this one is the 44th largest by planned enrollment of the 246 interventional ones that give a count, is one of 40 that started in 2026, is one of 239 with no phase, reaches primary completion later than 43 of the 70 other live ones, and was the 307th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →59 of the 343 studies in Depression with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Nisantasi University · Sites in Turkey
Ages 18+ · Healthy volunteers
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Istanbul University · Sites in Turkey
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 40–54 · Women only · Healthy volunteers
Hitit University · Sites in Turkey
Ages 50+ · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 45 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
343 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 40 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 60 across the 246 interventional studies, 107 across the 97 observational. Of the 258 that completed or were terminated, 6 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 343 have an industry lead sponsor. The 10 most frequent:
Ankara Medipol University is the lead sponsor of 56 studies on the registry; 10 are open to participants now.
Ankara Medipol University has 4 studies filed under Depression — fewer than ten, so there is no comparison to draw.
24 of the studies in Depression with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07517549Ordu UniversitySexual Health Education During Pregnancy | 2026-11-30 |
| NCT07718399Halic UniversitySpirulina Supplementation in Postmenopausal Women | 2026-12 |
| NCT07603804Istanbul University - CerrahpasaAccelerated iTBS for Major Depression | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 343 studies in Depression with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the effectiveness of a Meleis' Transition Theory-based education and counseling program on menopausal symptoms, perimenopausal depression, and menopause-specific quality of life among naturally menopausal women aged 45 to 55 years.
Participants will be randomly assigned to either the intervention group or the control group. The intervention group will receive a structured four-week education and counseling program based on Meleis' Transition Theory, supported by a secure online messaging group and follow-up counseling sessions. The control group will receive routine care and standard information during the study period and will be offered a one-day educational session after completion of the final assessment.
The outcomes will be measured at baseline and Week 16 using the Menopause Rating Scale, the Perimenopausal Depression Scale, and the Menopause-Specific Quality of Life Questionnaire-II.
Menopause is a developmental life transition associated with biological, psychological, and social changes that may negatively affect women's health, well-being, and quality of life. During the menopausal transition, women may experience vasomotor symptoms, sleep disturbances, mood changes, depressive symptoms, urogenital symptoms, and difficulties in adapting to new life roles.
Meleis' Transition Theory provides a conceptual framework for understanding and supporting individuals during life transitions. The theory emphasizes the role of healthcare professionals in facilitating healthy transitions through education, counseling, support, and the strengthening of coping strategies.
This study is designed as a two-arm randomized controlled trial. The study population consists of naturally menopausal women registered at Dikmen Sokullu Mehmet Pasa Family Health Center, a primary healthcare institution affiliated with the Ankara Provincial Health Directorate in Turkey. A total of 114 women who meet the eligibility criteria and provide written informed consent will be recruited.
Participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group using computer-generated simple randomization through Randomizer.org. To minimize bias, statistical analyses will be conducted by a blinded statistician.
Participants in the intervention group will receive a Meleis' Transition Theory-Based Education and Counseling Program. The program consists of four weekly face-to-face educational sessions lasting approximately 90 minutes each. In addition, a secure WhatsApp support group will be established exclusively for participants in the intervention group to provide motivational support and ongoing communication. Follow-up counseling and support meetings will also be conducted during the study period.
The educational content includes menopause and life transitions, facilitators and inhibitors of menopausal transition, physical, psychological, and social effects of menopause, menopausal symptoms, perimenopausal depression, quality of life, social support systems, coping strategies, and self-management skills.
Participants in the control group will receive routine care and standard information during the study period. After completion of the Week 16 final assessment, they will be offered a one-day educational session based on the intervention content.
Outcome assessments will be conducted at baseline and Week 16. Data will be collected using the Personal Information Form, the Menopause Rating Scale, the Perimenopausal Depression Scale, and the Menopause-Specific Quality of Life Questionnaire-II.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the intervention group will receive a structured education and counseling program based on Meleis' Transition Theory. The intervention consists of four weekly face-to-face educational sessions lasting approximately 90 minutes each, a secure online messaging support group, continuous motivational support, and follow-up counseling sessions throughout the study period.
Behavioral: Meleis' Transition Theory-Based Education and Counseling Program
Participants assigned to the control group will receive routine care and standard information during the study period. Following completion of the Week 16 assessment, participants will be offered a one-day educational session based on the intervention content.
Other: Standard Information
The intervention is a structured education and counseling program developed according to Meleis' Transition Theory. The program consists of four weekly group sessions lasting approximately 90 minutes each. Educational content includes menopause and life transitions, facilitators and inhibitors of menopausal transition, physical and psychological effects of menopause, social support systems, coping strategies, and self-management skills. Participants also receive ongoing support through a secure online messaging platform and follow-up counseling sessions.
Participants receive routine care and standard health information available in primary healthcare settings during the study period. After completion of final assessments, participants are offered a one-day educational session.
Change in Menopausal Symptoms
Menopausal symptom severity will be assessed using the Menopause Rating Scale. The Menopause Rating Scale is an 11-item instrument evaluating somatic, psychological, and urogenital symptoms. Total scores range from 0 to 44. Higher scores indicate more severe menopausal symptoms.
Time frame: Baseline and Week 16
Change in Perimenopausal Depression
The Meno-D is a 12-item self-report scale developed to evaluate perimenopausal depressive symptoms. Items are scored on a 4-point Likert scale. Total scores range from 0 to 48, with higher scores indicating greater severity of perimenopausal depression. Scores of 20-24 indicate mild depression requiring follow-up, 24-32 indicate moderate depression requiring treatment, and scores ≥32 indicate severe depression requiring treatment
Time frame: Baseline and Week 16
Change in Menopause-Specific Quality of Life
The MENQOL-II is a 29-item instrument assessing the impact of menopausal symptoms on quality of life across vasomotor, psychosocial, physical, and sexual domains. Total scores range from 29 to 232, with higher scores indicating a greater negative impact of menopausal symptoms on quality of life.
Time frame: Baseline and Week 16
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Medipol University